Literature DB >> 11857499

Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy.

Dominique Baeten1, Pieter Demetter, Claude A Cuvelier, Elli Kruithof, Nancy Van Damme, Martine De Vos, Eric M Veys, Filip De Keyser.   

Abstract

The objective of this study was to investigate CD163+ macrophages in the synovial membrane of patients with spondyloarthropathy (SpA). Immunohistochemistry was performed on synovium of 17 SpA and 18 rheumatoid arthritis (RA) patients, on colonic biopsies of 16 SpA patients and ten healthy controls, and on paired synovial biopsies of eight SpA patients, before and after anti-TNFalpha therapy. Phenotype and cytokine production were analysed by flow cytometry. CD163+ macrophages were increased in the synovial lining and sublining in SpA versus RA, as well as in colonic lamina propria in SpA versus controls. The number of CD163+ macrophages in the synovial sublining correlated with C-reactive protein levels and erythrocyte sedimentation rate. Paralleling the increase of CD163, HLA-DR was increased in the synovial lining and sublining of SpA. In contrast, the co-stimulatory molecules CD80 and CD86 and the dendritic cell markers CD1a and CD83 were scarce in SpA synovium. Flow cytometry indicated that CD163+ macrophages expressed high levels of HLA-DR and could produce in vitro tumour necrosis factor alpha (TNFalpha) but not interleukin-10 (IL-10). Finally, anti-TNFalpha therapy in vivo induced a decrease of CD163+ macrophages in the synovial lining and sublining. In conclusion, macrophages expressing the scavenger receptor CD163 are increased in synovium and in colonic mucosa in SpA, highlighting the relationship between joint and gut in this disease. The correlation with inflammatory parameters, the expression of HLA-DR, the production of TNFalpha but not IL-10, and the reduction by anti-TNFalpha therapy support a role for CD163+ macrophages in the synovial inflammation in SpA. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857499     DOI: 10.1002/path.1044

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  53 in total

1.  Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy.

Authors:  E Kruithof; D Baeten; F Van den Bosch; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2004-09-23       Impact factor: 19.103

Review 2.  The transition of acute to chronic bowel inflammation in spondyloarthritis.

Authors:  Liesbet Van Praet; Peggy Jacques; Filip Van den Bosch; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2012-04-17       Impact factor: 20.543

3.  Overexpression and unique rearrangement of VH2 transcripts in immunoglobulin variable heavy chain genes in ankylosing spondylitis patients.

Authors:  Yeon Joo Kim; Na Young Kim; Min Kyung Lee; Hyo Jin Choi; Han Joo Baek; Chang Hoon Nam
Journal:  Exp Mol Med       Date:  2010-05-31       Impact factor: 8.718

Review 4.  A possible link between Crohn's disease and ankylosing spondylitis via Klebsiella infections.

Authors:  Alan Ebringer; Taha Rashid; Harmale Tiwana; Clyde Wilson
Journal:  Clin Rheumatol       Date:  2006-08-29       Impact factor: 2.980

Review 5.  Pathogenesis of spondyloarthritis: insights from synovial membrane studies.

Authors:  Leen De Rycke; Elli Kruithof; Bernard Vandooren; Paul P Tak; Dominique Baeten
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

6.  Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis.

Authors:  D Baeten; J Houbiers; E Kruithof; B Vandooren; F Van den Bosch; A M Boots; E M Veys; A M M Miltenburg; F De Keyser
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

7.  Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment.

Authors:  M Rihl; E Kruithof; C Barthel; F De Keyser; E M Veys; H Zeidler; D T Y Yu; J G Kuipers; D Baeten
Journal:  Ann Rheum Dis       Date:  2005-04-07       Impact factor: 19.103

Review 8.  Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis.

Authors:  M L Stoll
Journal:  Clin Exp Rheumatol       Date:  2011-04-19       Impact factor: 4.473

Review 9.  The role of the gut and microbes in the pathogenesis of spondyloarthritis.

Authors:  Mark Asquith; Dirk Elewaut; Phoebe Lin; James T Rosenbaum
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-11-15       Impact factor: 4.098

10.  Circulating levels of the shed scavenger receptor sCD163 and association with outcome of critically ill patients.

Authors:  Catherine Ingels; Holger J Møller; Troels K Hansen; Pieter J Wouters; Ilse Vanhorebeek; Greet Van den Berghe
Journal:  J Clin Immunol       Date:  2012-11-13       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.